Osteoarthritis gene therapy

Gene Therapy

Volumn 11, Issue 4, 2004, Pages 379-389

  Evans, C H ^a   Gouze, J N ^a   Gouze, E ^a   Robbins, P D ^b   Ghivizzani, S C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; Cartilage; Clinical trial; IL 1Ra; Joint; Synovium

Indexed keywords

ANALGESIC AGENT; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE 2; FIBROBLAST GROWTH FACTOR; FRUCTOKINASE; HYALURONIC ACID; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 4; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OSTEOGENIC PROTEIN 1; PARACETAMOL; PROTEIN BCL 2; SERINE PROTEINASE INHIBITOR; SMAD PROTEIN; SOMATOMEDIN C; STEROID; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1;

ADENO ASSOCIATED VIRUS; ARTHROSCOPY; ARTICULAR CARTILAGE; CLINICAL FEATURE; CLINICAL TRIAL; DNA MODIFICATION; GENE EXPRESSION; GENE TRANSFER; HISTOPATHOLOGY; HUMAN; JOINT CAVITY; JOINT PROSTHESIS; NONHUMAN; OSTEOARTHRITIS; OSTEOTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNOVIUM; VIRAL GENE DELIVERY SYSTEM; WEIGHT BEARING;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; OSTEOARTHRITIS; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS;

ADENO-ASSOCIATED VIRUS;

EID: 1342285045     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302196     Document Type: Review

References (134)

1. Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002; 14: 573-577.
2. Praemer A, Furner S, Rice D. Musculoskeletal Conditions in the United States. American Academy of Orthopaedic Surgeons: Rosemont, IL, 1992.
3. Elders MJ. The increasing impact of arthritis on public health. J Rheumatol Suppl 2000; 60: 6-8.
4. Evans CH, Robbins PD. Potential treatment of osteoarthritis by gene therapy. Rheum Dis Clin North Am 1999; 25: 333-344.
5. Evans CH. Gene therapies for osteoarthritis. Curr Rheumatol Rep 2003, in press.
6. Dieppe P et al. Osteoarthritis. Clin Evid 2002; 7: 1071-1090.
7. Hunziker EB. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage 2002; 10: 432-463.
8. Archer CW, Francis-West P. The chondrocyte. Int J Biochem Cell Biol 2003; 35: 401-404.
9. Evans CH. Catilage and synovium. In: Baratz ME, Watson AD, Imbriglia JE (eds). Orthopaedic Surgery. The Essentials. Thieme: New York, 1999, pp 33-46.
10. Felson D ed. Osteoarthritis joint pain. Novartis Found Symp 2003.
11. Swagerty Jr DL, Hellinger D. Radiographic assessment of osteoarthritis. Am Fam Physician 2001; 64: 279-286.
12. Ravaud F, Ayral X, Dougados M. Radiologic progression of hip and knee osteoarthritis. Osteoarthritis Cartilage 1999; 7: 222-229.
13. Gardner DL. The nature and causes of osteoarthrosis. BMJ (Clin Res Ed) 1983; 286: 418-424.
14. Hough Jr AJ, Webber RJ. Pathology of the meniscus. Clin Orthop 1990; 252: 32-40.
15. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001; 44: 1237-1247.
16. Evans CH et al. Experimental arthritis induced by intraarticular injection of allogenic cartilaginous particles into rabbit knees. Arthritis Rheum 1984; 27: 200-207.
17. McCarthy GM. Crystal-induced inflammation and cartilage degradation. Curr Rheumatol Rep 1999; 1: 101-106.
18. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39: 237-246.
19. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999; 40: 1-11.
20. Smith MD et al. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997; 24: 365-371.
21. Poole AR. An introduction to the pathophysiology of osteoarthritis. Front Biosci 1999; 4: D662-670.
22. Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 2001; 3: 107-113.
23. Blanco FJ et al. Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum 1998; 41: 284-289.
24. Aigner T et al. Apoptotic cell death is not a widespread phenomenon in normal aging and osteoarthritis human articular knee cartilage: a study of proliferation, programmed cell death (apoptosis), and viability of chondrocytes in normal and osteoarthritic human knee cartilage. Arthritis Rheum 2001; 44: 1304-1312.
25. Aigner T, Kim HA. Apoptosis and cellular vitality: issues in osteoarthritic cartilage degeneration. Arthritis Rheum 2002; 46: 1986-1996.
26. Aigner T et al. Roles of chondrocytes in the pathogenesis of osteoarthritis. Curr Opin Rheumatol 2002; 14: 578-584.
27. Aigner T et al. Suppression of cartilage matrix gene expression in upper zone chondrocytes of osteoarthritic cartilage. Arthritis Rheum 1997; 40: 562-569.
28. Adams ME, Brandt KD. Hypertrophic repair of canine articular cartilage in osteoarthritis after anterior cruciate ligament transection. J Rheumatol 1991; 18: 428-435.
29. Poole AR et al. Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis 2002; 61 (Suppl 2): ii78-ii81.
30. Aigner T et al. Independent expression of fibril-forming collagens I, II, and III in chondrocytes of human osteoarthritic cartilage. J Clin Invest 1993; 91: 829-837.
31. Smith RL. Degradative enzymes in osteoarthritis. Front Biosci 1999; 4: D704-12.
32. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3: 207-214.
33. Blobel CP. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. Inflamm Res 2002; 51: 83-84.
34. Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003; 5: 94-103.
35. Evans CH, Watkins SC, Stefanovic-Racic M. Nitric oxide and cartilage metabolism. Methods Enzymol 1996; 269: 75-88.
36. Tiku ML, Gupta S, Deshmukh DR. Aggrecan degradation in chondrocytes is mediated by reactive oxygen species and protected by antioxidants. Free Radic Res 1999; 30: 395-405.
37. Clancy R et al. Activation of stress-activated protein kinase in osteoarthritic cartilage: evidence for nitric oxide dependence. Osteoarthritis Cartilage 2001; 9: 294-299.
38. Abramson SB. The role of COX-2 produced by cartilage in arthritis. Osteoarthritis Cartilage 1999; 7: 380-381.
39. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage 1998; 6: 374-376.
40. Koshy PJ et al. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002; 61: 704-713.
41. Olee T et al. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol 1999; 162: 1096-1100.
42. Yuan GH et al. The role of C-C chemokines and their receptors in osteoarthritis. Arthritis Rheum 2001; 44: 1056-1070.
43. Pulsatelli L et al. Chemokine production by human chondrocytes. J Rheumatol 1999; 26: 1992-2001.
44. Homandberg GA, Wen C, Hui F. Cartilage damaging activities of fibronectin fragments derived from cartilage and synovial fluid. Osteoarthritis Cartilage 1998; 6: 231-244.
45. Cheung HS. The role of crystals in articular tissue degeneration. Curr Rheumatol Rep 1999; 1: 128-131.
46. Saudek DM, Kay J. Advanced glycation endproducts and osteoarthritis. Curr Rheumatol Rep 2003; 5: 33-40.
47. Grodzinsky AJ et al. Cartilage tissue remodeling in response to mechanical forces. Annu Rev Biomed Eng 2000; 2: 691-713.
48. Deschner J et al. Signal transduction by mechanical strain in chondrocytes. Curr Opin Clin Nutr Metab Care 2003; 6: 289-293.
49. Tyler JA. Insulin-like growth factor 1 can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J 1989; 260: 543-548.
50. Loeser RF, Shanker G. Autocrine stimulation by insulin-like growth factor 1 and insulin-like growth factor 2 mediates chondrocyte survival in vitro. Arthritis Rheum 2000; 43: 1552-1559.
51. Fortier LA, Nixon AJ, Lust G. Phenotypic expression of equine articular chondrocytes grown in three-dimensional cultures supplemented with supraphysiologic concentrations of insulin-like growth factor-1. Am J Vet Res 2002; 63: 301-305.
52. Martel-Pelletier J et al. IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis. Inflamm Res 1998; 47: 90-100.
53. Loeser RF et al. Reduction in the chondrocyte response to insulin-like growth factor 1 in aging and osteoarthritis: studies in a non-human primate model of naturally occurring disease. Arthritis Rheum 2000; 43: 2110-2120.
54. Studer RK et al. Nitric oxide inhibits chondrocyte response to IGF-1: inhibition of IGF-IRbeta tyrosine phosphorylation. Am J Physiol Cell Physiol 2000; 279: C961-C969.
55. Lafeber FP et al. Transforming growth factor-beta predominantly stimulates phenotypically changed chondrocytes in osteoarthritic human cartilage. J Rheumatol 1997; 24: 536-542.
56. Palmer G et al. Development of gene-based therapies for cartilage repair. Crit Rev Eukaryot Gene Expr 2002; 12: 259-273.
57. Kafienah W et al. Inhibition of cartilage degradation: a combined tissue engineering and gene therapy approach. Arthritis Rheum 2003; 48: 709-718.
58. Brandt KD. Animal models of osteoarthritis. Biorheology 2002; 39: 221-235.
59. van den Berg WB. Lessons from animal models of osteoarthritis. Curr Opin Rheumatol 2001; 13: 452-456.
60. McDevitt C, Gilbertson E, Muir H. An experimental model of osteoarthritis; early morphological and biochemical changes. J Bone Joint Surg Br 1977; 59: 24-35.
61. Hochberg MC et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995; 38: 1541-1546.
62. Hochberg MC et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995; 38: 1535-1540.
63. Chard J, Dieppe P. Update: treatment of osteoarthritis. Arthritis Rheum 2002; 47: 686-690.
64. Garrett Jr W. Evaluation and treatment of the arthritic knee. J Bone Joint Surg Am 2003; 85-A: 156-157.
65. Bradley JD. Joint irrigation as treatment for osteoarthritis. Curr Rheumatol Rep 2003; 5: 20-26.
66. Moseley JB et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347: 81-88.
67. Buckwalter JA, Lohmander S. Operative treatment of osteoarthrosis. Current practice and future development. J Bone Joint Surg Am 1994; 76: 1405-1418.
68. Hungerford DS, Jones LC. Glucosamine and chondroitin sulfate are effective in the management of osteoarthritis. J Arthroplasty 2003; 18 (3 Suppl 1): 5-9.
69. Close DR. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 2001; 60 (Suppl 3): iii62-iii67.
70. Darlington LG, Stone TW. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br J Nutr 2001; 85: 251-269.
71. Goldring MB. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 2001; 1: 817-829.
72. MacGregor AJ et al. The genetic contribution to radiographic hip osteoarthritis in women: results of a classic twin study. Arthritis Rheum 2000; 43: 2410-2416.
73. Wordsworth P. Genes and arthritis. Br Med Bull 1995; 51: 249-266.
74. Ala-Kokko L et al. Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia. Proc Natl Acad Sci USA 1990; 87: 6565-6568.
75. Bandara G et al. Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 1992; 11: 227-231.
76. Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Therapy 2003; 10: 902-911.
77. Gouze E et al. Gene therapy for rheumatoid arthritis. Curr Rheumatol Rep 2001; 3: 79-85.
78. Herndon JH, Robbins PD, Evans CH. Arthritis: is the cure in your genes? J Bone Joint Surg Am 1999; 81: 152-157.
79. Evans CH et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999; 42: 1-16.
80. Evans CH et al. Using gene therapy to protect and restore cartilage. Clin Orthop 2000 (Suppl 379): S214-S219.
81. Ghivizzani SC et al. Direct gene delivery strategies for the treatment of rheumatoid arthritis. Drug Discov Today 2001; 6: 259-267.
82. Oligino TJ et al. Vector systems for gene transfer to joints. Clin Orthop 2000 (Suppl 379): S17-30.
83. Nita I et al. Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996; 39: 820-828.
84. Bandara G et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993; 90: 10764-10768.
85. Gouze E et al. In vivo gene delivery to synovium by lentiviral vectors. Mol Ther 2002; 5: 397-404.
86. Mi Z et al. Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum 2000; 43: 2563-2570.
87. Mi Z et al. Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor beta 1 into rabbit knees. Arthritis Res Ther 2003; 5: R132-9.
88. Bakker AC et al. Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. Osteoarthritis Cartilage 2001; 9: 128-136.
89. Gelse K et al. Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer. Arthritis Rheum 2001; 44: 1943-1953.
90. Arend WP, Evans CH. Interleukin-1 receptor antagonist. In: Thomson AW, Lotz MT (eds). The Cytokine Handbook. Academic Press: London, 2003, pp 669-708.
91. Nixon AJ et al. Gene mediated restoration of cartilage matrix by combination insulin-like growth factor-1/interleukin-1 receptor antagonist therapy. Gene Therapy 2003, in press.
92. Gouze JN et al. Adenovirus-mediated gene transfer to glutamine:fructose-6-phosphate amidotransferase antagonizes the effects of interleukin-1 beta on rat chondrocytes. Osteoarthritis Cartilage 2003, in press.
93. Palmer GD et al. Gene transfer to articular chondrocytes with recombinant adenovirus. Methods Mol Biol 2003; 215: 235-246.
94. Samuel RE et al. Delivery of plasmid DNA to articular chondrocytes via novel collagen-glycosaminoglycan matrices. Hum Gene Ther 2002; 13: 791-802.
95. Kang R et al. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarthritis Cartilage 1997; 5: 139-143.
96. Stove J et al. Lipofection of rabbit chondrocytes and long lasting expression of a lacZ reporter system in alginate beads. Osteoarthritis Cartilage 2002; 10: 212-217.
97. Madry H, Zurakowski D, Trippel SB. Overexpression of human insulin-like growth factor-I promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation. Gene Therapy 2001; 8: 1443-1449.
98. Shuler FD et al. Increased matrix synthesis following adenoviral transfer of a transforming growth factor beta1 gene into articular chondrocytes. J Orthop Res 2000; 18: 585-592.
99. Brower-Toland BD et al. Direct adenovirus-mediated insulin-like growth factor I gene transfer enhances transplant chondrocyte function. Hum Gene Ther 2001; 12: 117-129.
100. Smith P et al. Genetic enhancement of matrix synthesis by articular chondrocytes: comparison of different growth factor genes in the presence and absence of interleukin-1. Arthritis Rheum 2000; 43: 1156-1164.
101. Ikeda T et al. Adenovirus mediated gene delivery to the joints of guinea pigs. J Rheumatol 1998; 25: 1666-1673.
102. Nishida K et al. Potential applications of gene therapy to the treatment of intervertebral disc disorders. Clin Orthop 2000 (Suppl 379): 3795: S234-41.
103. Baragi VM et al. Transplantation of adenovirally transduced allogeneic chondrocytes into articular cartilage defects in vivo. Osteoarthritis Cartilage 1997; 5: 275-282.
104. Brittberg M et al. Autologous chondrocytes used for articular cartilage repair: an update. Clin Orthop 2001 (391 Suppl): S337-S348.
105. Doherty PJ et al. Adhesion of transplanted chondrocytes onto cartilage in vitro and in vivo. J Rheumatol 2000; 27: 1725-1731.
106. Baragi VM et al. Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation. J Clin Invest 1995; 96: 2454-2460.
107. Dinarello CA. Interleukin-1 family. In: Thomson AW, Lotz MT (eds). The Cytokine Handbook. Academic Press: London, 2003, pp 643-668.
108. Pelletier JP et al. Coordinate synthesis of stromelysin, interleukin-1, and oncogene proteins in experimental osteoarthritis - an immunohistochemical study. Am J Pathol 1993; 142: 95-105.
109. Caron JP et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535-1544.
110. Attur MG et al. Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol 2002; 168: 2001-2010.
111. Attur MG et al. Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem 2000; 275: 40307-40315.
112. Attur MG et al. Autocrine production of IL-1 beta by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc Assoc Am Physicians 1998; 110: 65-72.
113. Martel-Pelletier J et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum 1992; 35: 530-540.
114. Melchiorri C et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998; 41: 2165-2174.
115. Towle CA et al. Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/paracrine role in pathogenesis. Osteoarthritis Cartilage 1997; 5: 293-300.
116. Eger W et al. Human knee and ankle cartilage explants: catabolic differences. J Orthop Res 2002; 20: 526-534.
117. Cole AA, Kuettner KE. Molecular basis for differences between human joints. Cell Mol Life Sci 2002; 59: 19-26.
118. Kary S, Burmester GR. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Pract 2003; 57: 231-234.
119. Bresnihan B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. BioDrugs 2001; 15: 87-97.
120. Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42 (Suppl 2): ii29-ii35.
121. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2001; 30 (5 Suppl 2): 17-20.
122. Bendele A et al. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42: 498-506.
123. Evans CH, Robbins PD. The interleukin-1 receptor antagonist and its delivery by gene transfer. Receptor 1994; 4: 9-15.
124. Pelletier JP et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012-1019.
125. Frisbie DD et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Therapy 2002; 9: 12-20.
126. Fernandes J et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999; 154: 1159-1169.
127. Otani K et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996; 156: 3558-3562.
128. Evans CH et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261-1280.
129. Boggs SS et al. Prolonged systemic expression of human IL-1 receptor antagonist (hIL-1ra) in mice reconstituted with hematopoietic cells transduced with a retrovirus carrying the hIL-1ra cDNA. Gene Therapy 1995; 2: 632-638.
130. Evans CH et al. Clinical trials in the gene therapy of arthritis. Clin Orthop 2000 (Suppl 379): S300-S307.
131. Gouze E et al. Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation. Mol Ther 2003; 7: 460-466.
132. Goater J et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol 2000; 27: 983-989.
133. Pan RY et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000; 43: 289-297.
134. Kang R et al. The Marshall R. Urist Young Investigator Award. Orthopaedic applications of gene therapy. From concept to clinic. Clin Orthop 2000: 324-337.